Shingles News and Research

RSS

Shingles (herpes zoster) is an outbreak of rash or blisters on the skin that is caused by the same virus that causes chickenpox — the varicella-zoster virus. The first sign of shingles is often burning or tingling pain, or sometimes numbness or itch, in one particular location on only one side of the body.

Inhibitex third quarter revenue increases to $1.3 million

Inhibitex, Inc. today announced its financial results for the third quarter ended September 30, 2011 and provided an update on several recent corporate developments, including top-line safety and antiviral data from the first cohort in its ongoing clinical trial designed to evaluate higher doses of INX-189, an oral nucleotide polymerase inhibitor, being developed to treat chronic infections caused by hepatitis C virus (HCV), administered as monotherapy or in combination with ribavirin for seven days.

4 Nov 2011

Inhibitex initiates INX-189 combination Phase 2 trial in HCV-infected genotype 2/3 patients

Inhibitex, Inc., announced today that it has recently commenced dosing in a 90-patient randomized, placebo controlled, treatment guided, Phase 2 clinical trial to evaluate the safety, tolerability and antiviral activity of INX-189 in combination with pegylated interferon and ribavirin in chronic HCV-infected genotype 2 and 3 treatment naïve patients.

19 Sep 2011

Aestus to develop ATx09-002 for treatment of neuropathic pain

Aestus Therapeutics, Inc. and Prosidion Ltd., a wholly owned subsidiary of Astellas Pharma Inc., announced today a license agreement providing Aestus with exclusive, world-wide rights to the Prosidion investigational product PSN-357.

19 Sep 2011

Spinifex initiates EMA401 Phase 2 trial in postherpetic neuralgia

Spinifex Pharmaceuticals, an Australian pain drug development company, today announced the first patients have been treated in its Phase 2 clinical trial of EMA401 in postherpetic neuralgia (PHN), a painful condition that develops in some patients following herpes zoster (shingles) and where existing therapy does not relieve pain in all individuals.

19 Sep 2011

Georgia reminds adults to get vaccinated

Vaccines aren't just for kids, adults need protection too! September 18 kick starts National Adult Immunization Awareness Week and the Georgia Department of Public Health reminds Georgians that you never outgrow the need for vaccines.

16 Sep 2011

BioLineRx, Tel Aviv University sign license agreement to develop and commercialize BL-7050

BioLineRx, a biopharmaceutical development company, today announced that it has signed a worldwide, exclusive license agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel Aviv University, for the development and commercialization of BL-7050, a novel, orally-available treatment for neuropathic and inflammatory pain.

7 Sep 2011

DOJ investigates Miss. mental health care; N.H. pharmacists win permission to vaccinate

The Justice Department is now investigating Mississippi's mental health system, seeking to determine whether those suffering from mental illness are receiving appropriate treatment. Justice Department officials are expected to return to the Magnolia State later this month, and it's a safe bet they will make similar recommendations against Mississippi as they have against Virginia and other states, said Region 8 Executive Director Dave Van.

7 Sep 2011

U-M offers transplantation for patients with bile duct cancer

Robert "Buzz" Gehle thought the itchy rash he was experiencing was a recurrence of an earlier case of shingles. But when his doctor saw he was also jaundiced, he immediately knew there was a problem with Gehle's liver.

30 Aug 2011

IOM report: Few health problems are clearly associated with vaccines

An analysis of more than 1,000 research articles concluded that few health problems are caused by or clearly associated with vaccines.

26 Aug 2011

Spinifex secures AU$6.25 million in expanded Series B funding

Spinifex Pharmaceuticals, an Australian pain drug development company, today announced it has secured a further AU$6.25 million of venture capital investment from GBS Venture Partners Limited, Brandon Capital Partners Pty Limited, Uniseed Management Pty Limited and UniQuest Pty Limited to fund the development of its pain management drug, EMA401.

23 Aug 2011

Inhibitex second quarter net loss decreases to $5.3 million

Inhibitex, Inc. today announced its financial results for the second quarter ended June 30, 2011 and provided an update on several recent clinical and corporate developments.

8 Aug 2011

Dow second quarter sales increase to $16.0 billion

Dow reported earnings of $0.84 per share. This compares with reported earnings of $0.50 per share in the same period last year.

27 Jul 2011

Chicken pox vaccine reduced related deaths by 88%

The team of researchers found that although in 2006 a second dose was added to the vaccination roster, the decrease in deaths occurred largely during the time when just one shot was recommended. While chickenpox-related deaths are now relatively rare, the new two-dose regimen may eliminate them altogether, they said. The double dose will further reduce sick days and medical care associated with chickenpox and its complications, the study authors said.

25 Jul 2011

New 3D herpes infection model brings hope

Herpes infections on the lips, in the eyes or on the nose are painful, long-lasting and unpleasant. A new 3D herpes infection model brings hope: active ingredients and new treatments can be reliably tested with this model. Animal tests could soon be a thing of the past.

27 Jun 2011

Pfizer Lyrica Phase 3 study on Central Neuropathic Pain meets primary endpoint

Pfizer Inc. announced today that top-line results for Lyrica Study A0081107 - Central Neuropathic Pain Following Spinal Cord Injury - demonstrated that the study met its primary endpoint: positive efficacy in reducing Central Neuropathic Pain following Spinal Cord Injury with Lyrica compared to placebo.

22 Jun 2011

Tips for preventing outdoor home-related injury: AANS

The nail-gun neck injury and treatment incurred by a 25-year-old carpenter described in the Journal of Neurosurgery: Spine article might read like an oddity, but nail guns are actually a common form of penetrating low-velocity injury. What made this case unique was that the patient incurred a penetrating wound to the cervical spine by a barbed nail lodged in close proximity to the right vertebral artery.

9 Jun 2011

Adults with herpes zoster may face higher risk of multiple sclerosis

Taiwanese investigators have found that there can be a significantly higher risk of multiple sclerosis (MS) occurring in the year following a shingles, or herpes zoster, attack.

9 Jun 2011

Skin cell-derived CGRP-beta may cause chronic pain

A new study may explain why only 50% of patients experiencing chronic nerve pain achieve even partial relief from existing therapeutics. The study, published in the June 6 online version of the international research journal PAIN, reveals that certain types of chronic pain may be caused by signals from the skin itself, rather than damage to nerves within the skin, as previously thought.

9 Jun 2011

Patients with body dysmorphic disorder have less brain activity in visual processing

People suffering from body dysmorphic disorder, or BDD - a severe mental illness characterized by debilitating misperceptions that one appears disfigured and ugly - process visual information abnormally, even when looking at inanimate objects, according to a new UCLA study.

27 May 2011

Pfizer presents SA3Ag staphylococcal vaccine Phase 1 trial data at ECCMID/ICC

Inhibitex, Inc., announced today that Pfizer Inc. presented safety and immunogenicity data from a Phase 1 double-blind randomized placebo controlled study in 408 healthy volunteers of a novel three antigen Staphylococcus aureus investigational vaccine at the 21st European Congress of Clinical Microbiology and Infectious Diseases and 27th International Congress of Chemotherapy in Milan, Italy.

10 May 2011